"Building on our knowledge base in chemistry, we have also planned to foray into the pharma sector for manufacturing and export of early intermediates. We see synergy at the R&D manufacturing and customer end in this area," the company management said in its annual report.
The company is already working closely with its global partners, focusing on two to three high-potential molecules for the Indian market under the in-licensing arrangement.
"We have made an investment to the tune of Rs 321.44 crore in FY16 to set up two new state-of-the-art manufacturing facilities at Jambusar and R&D centre at Udaipur.
The company said its product development team is working on a rich pipeline of products that are being evaluated and are in different stages of registration and it will continue with its tradition of introducing one-two new products every year.
"To meet with the requirement of our global customers, combined efforts of our R&D, product development and manufacturing teams resulted in commercialising three new high potential molecules during the year.
The agrochemicals industry is expected to play a pivotal role in driving food security for India, which is on its way to replace China as the world's most populous country.
With dwindling land under cultivation and an alarmingly lower portion of that under irrigation, the need to increase farm productivity with efficient use of plant nutrients and protection is pressing.
Estimates suggest that the country loses more than 30 per cent of its farm produce to pests and weeds, which warrants containment through adequate usage of plant protection chemicals, Singhal said.
Its revenue grew by 8.1 per cent to Rs 2,097 crore, while net profit rose by 28.8 per cent at Rs 313 crore.
"In terms of order book position, we closed the year with a record high of USD 850 million. The robust order book with revenue visibility for coming years will continue to drive our investments towards further strengthening our capabilities," PI Industries Managing Director Mayank Singhal said.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
